Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Gilotrif
Afatinib is an irreversible ErbB family blocker tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. It acts by targeting EGFR, HER2, and HER4 receptors, thereby inhibiting tumor cell growth and proliferation. Afatinib is an oral medication, typically administered once daily.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.
Afatinib can cause severe diarrhea, interstitial lung disease/pneumonitis, and skin reactions. It can also cause liver toxicity and embryofetal toxicity.
Outcome:
Decreased afatinib levels, reduced efficacy
Mechanism:
Increased afatinib metabolism
Outcome:
Increased afatinib levels
Mechanism:
CYP3A4 inhibition
Outcome:
Slightly decreased afatinib absorption
Mechanism:
Increased gastric pH
Most likely new formulation: Extended-release afatinib (Year 2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of expanded indications for afatinib in other EGFR-mutant cancers within the next 5 years.
Kinase Inhibitor, Antineoplastic
Quinazoline